SERTAD4-AS1 suppresses pancreatic cancer progression by stabilizing SERTAD4 and inhibiting the Notch1 pathway

Yuchen Tang, Jie Wang, Jun Yao, Haoran Li, Bin Yi, Chengqing Yu, Yijun Wei, Jian Yang, Zixiang Zhang, Jian ZhouGenes 2025 · DOI

TL;DR

This study identifies a long non-coding RNA, SERTAD4-AS1, as a crucial suppressor of pancreatic cancer (PC) progression. It achieves this by stabilizing its related gene SERTAD4 and subsequently inhibiting the oncogenic Notch1 signaling pathway, offering a potential new therapeutic target for this deadly disease.

What Problem Does This Paper Address?

Pancreatic cancer (PC) remains a formidable malignancy with a grim prognosis. While long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer, the precise mechanisms by which many of them exert their effects, particularly those acting as natural antisense transcripts, are not fully understood. This paper aims to elucidate the specific molecular function of SERTAD4-AS1, a lncRNA, in PC and uncover its regulatory pathways to identify potential therapeutic avenues.

Methods

The researchers employed a multi-pronged approach to investigate SERTAD4-AS1's role:

  • Expression Analysis: They used Kaplan-Meier survival analysis, pan-cancer expression profiling (GENT2 database), and qRT-PCR on clinical samples to assess SERTAD4-AS1 expression levels and their correlation with patient survival and disease stage.
  • Functional Assays: Standard cell-based assays were used to evaluate the impact of SERTAD4-AS1 overexpression and knockdown on PC cell proliferation, colony formation, migration, and invasion. This included using lentivirus-mediated plasmids for gene manipulation.
  • Mechanistic Investigations:
    • RNA-FISH: To determine the subcellular localization of SERTAD4-AS1.
  • Bioinformatics: A lncRNA-mRNA interaction network was constructed using the Co-LncRNA database to predict potential targets.
  • Western Blotting: To measure protein levels of key signaling molecules, including Notch1, p-mTOR, p-AKT, and PTEN.
  • mRNA Stability Assays: Using Actinomycin D to assess the effect of SERTAD4-AS1 on SERTAD4 mRNA decay.
  • RNA Immunoprecipitation (RIP) and RNA Pull-down Assays: To identify proteins interacting with SERTAD4-AS1.
  • Dual-Luciferase Reporter Assays: To confirm the regulatory effect of NONO on SERTAD4 transcription.
  • Rescue Experiments: Using a Notch1 inhibitor (Tangeritin) and siRNA knockdown to confirm the functional dependency on specific pathways.

Datasets

  • GENT2 Database: Used for comprehensive pan-cancer expression profiling of SERTAD4-AS1.
  • The Cancer Genome Atlas (TCGA) dataset: Analyzed via GEPIA2 to assess the correlation between SERTAD4 and SERTAD4-AS1 expression in PC tissues.
  • Clinical Cohort: 50 paired patient samples from the First Affiliated Hospital of Soochow University were used for validation of SERTAD4-AS1 expression.
  • Not discussed in the paper: Specific datasets for training machine learning models or novel benchmarks were not introduced.

Key Insights and Ideas

  • SERTAD4-AS1 as a Prognostic Marker: Lower expression of SERTAD4-AS1 is significantly correlated with poorer survival outcomes in PC patients, particularly in stage II, highlighting its clinical relevance.
  • Dual Mechanism of SERTAD4 Regulation: SERTAD4-AS1 doesn't just stabilize SERTAD4 mRNA; it also directly interferes with NONO, a transcriptional repressor of SERTAD4. This dual action amplifies SERTAD4's expression.
  • Inhibition of Notch1 Pathway: The increased SERTAD4 expression, driven by SERTAD4-AS1, leads to the suppression of the Notch1 signaling pathway, a known driver of cancer progression. This is a critical link in the observed tumor-suppressive effect.
  • Interdependence of SERTAD4-AS1 and SERTAD4: The study demonstrates a functional interdependence, where the tumor-suppressive effects of SERTAD4-AS1 are mediated through SERTAD4.

Key Results

  • SERTAD4-AS1 expression was significantly down-regulated in PC tissues compared to adjacent non-tumor tissues and across multiple cancer types.
  • Overexpression of SERTAD4-AS1 inhibited PC cell proliferation, colony formation, migration, and invasion, while knockdown had the opposite effect.
  • SERTAD4-AS1 was shown to stabilize SERTAD4 mRNA by forming a double-stranded RNA structure.
  • SERTAD4-AS1 directly bound to NONO, preventing its transcriptional repression of SERTAD4.
  • Overexpression of SERTAD4-AS1 led to reduced Notch1 protein levels, suppressed mTOR and AKT phosphorylation, and increased PTEN expression.
  • These effects were reversed by inhibiting the Notch1 pathway, confirming its crucial role.
  • Knockdown of SERTAD4-AS1 led to increased proliferation and invasion, which could be rescued by SERTAD4 knockdown, demonstrating functional interdependence.

Limitations and Future Work

  • Subcellular Localization Nuances: While SERTAD4-AS1 was found in both nuclear and cytoplasmic compartments, the precise distribution and specific roles in each compartment warrant further investigation.
  • Broader Clinical Validation: While a cohort of 50 patients was used for validation, larger, multi-center studies would strengthen the prognostic significance of SERTAD4-AS1.
  • Therapeutic Strategy Development: The paper suggests targeting the SERTAD4-AS1/NONO/SERTAD4 axis or downstream effectors like the Notch1 pathway. Future work should focus on developing specific therapeutic interventions based on these findings.
  • In vivo Efficacy: While the study mentions xenograft models for SERTAD4, further in vivo studies specifically for SERTAD4-AS1's therapeutic potential would be valuable.

Summary updated

BibTeX
@inproceedings{tang2025sertad,
  author = {Yuchen Tang and Jie Wang and Jun Yao and Haoran Li and Bin Yi and Chengqing Yu and Yijun Wei and Jian Yang and Zixiang Zhang and Jian Zhou},
  title = {{SERTAD4-AS1 suppresses pancreatic cancer progression by stabilizing SERTAD4 and inhibiting the Notch1 pathway}},
  booktitle = {Genes},
  year = {2025},
  doi = {10.1016/j.gendis.2025.101870},
}
Figure